U.S. Markets open in 4 hrs 47 mins

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
73.46-2.64 (-3.47%)
At close: 4:00PM EDT

Castle Biosciences, Inc.

505 South Friendswood Drive
Suite 401
Friendswood, TX 77546
United States
866 788 9007
http://castlebiosciences.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees199

Key Executives

NameTitlePayExercisedYear Born
Mr. Derek J. MaetzoldFounder, CEO, Pres & Director1.02MN/A1962
Mr. Frank StokesChief Financial Officer656.26kN/A1970
Mr. Bernhard E. SpiessChief Bus. Officer528.35kN/A1960
Ms. Kristen M. Oelschlager R.N., RNChief Operating OfficerN/AN/A1968
Camilla ZuckeroExec. Director of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Alice Bahner IzzoVP of MarketingN/AN/AN/A
Mr. Toby W. JuvenalChief Commercial OfficerN/AN/A1961
Dr. Robert W. CookSr. VP of R&DN/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Corporate Governance

Castle Biosciences, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.